News | March 18, 2009

Vicor Technologies Joins University of Rochester, Catalan Institute in Sudden Cardiac Death Study

March 18, 2009 - Vicor Technologies Inc. has entered into a collaborative research agreement with the University of Rochester and the Catalan Institute of Cardiovascular Sciences in Barcelona to study sudden cardiac death.
According to the agreement, Vicor's PD2i Cardiac Analyzer will be used by University of Rochester personnel to identify which of the 651 congestive heart failure patients who participated in the Merte Subita en Insufficiencia Cardiaca (MUSIC) Trial suffered sudden cardiac death. During the average 44 months MUSIC Trial participants were followed, 52 died from sudden cardiac death.
The PD2i algorithm is a deterministic, non-linear measure that analyzes electrophysiological potentials to predict future pathological events with a high degree of accuracy in target populations. The PD2i Cardiac Analyzer is based on the algorithm, which is believed to accurately risk stratify patients into those who are at high or low risk of suffering a fatal arrhythmic event or sudden cardiac death within a six month time frame.
The company expects to have the results of its MUSIC Trial data analysis during the second quarter of 2009.
For more information: www.vicortech.com.

Related Content

ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study| June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study| August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init